Pharmaceuticals, Biotechnology and Life Sciences
Oncology drug specialist ADC Therapeutics has continued with its Phase I clinical trial of combination of ADCT-402 (loncastuximab tesirine) with Pharmacyclics LLC’s ibrutinib, by dosing patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
ADC Therapeutics, oncology drug specialist started the Phase I clinical testing ADCT-601 on patients with selected solid tumors that are locally advanced or metastatic.
ADC Therapeutics, an oncology drug discovery and development company, has dosed first patient in its Phase Ib clinical trial of ADCT-301 in patients with selected solid tumors that are locally advanced or metastatic.
ADC Therapeutics has dosed the first patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), in a Phase I/II…